Why the study?
Surgical treatment for tricuspid regurgitation is limited by heightened surgical risk and delayed presentation, driving rapid technological advancements in transcatheter tricuspid valve procedures.
Answers are grounded in this paper and cite their sources.
This review provides an updated overview of transcatheter tricuspid valve procedures, alternative therapies, and patient selection standards for tricuspid regurgitation.
Tricuspid regurgitation (TR) is an intricate disorder that has a negative outlook, while surgical treatment is linked to increased mortality. Primary TR occurs due to a structural defect in the tricuspid valve (TV), while secondary TR is a more prevalent condition often associated with pulmonary hypertension, heart failure, and atrial fibrillation. The use of specific surgical procedures to improve TR is limited in everyday clinical practice due to the heightened surgical risk and delayed patient presentation. The development of other transcatheter heart valve procedures has led to a significant increase in transcatheter TV operations, which can be attributed to certain technological advancements. This review aims to provide an updated overview of transcatheter TV procedures, available alternative therapies, and standards for patient selection. It will also highlight the current state of development in this field, which is characterized by rapid progress and numerous ongoing clinical trials.
No takes yet. Share an insight, caveat, or question.
Synetos et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: